These findings provide a rationale for the evaluation of IL-6 inhibitors, such as tocilizumab, and Janus kinase/signal transducer and activation of transcription (JAK/STAT) inhibitors for the treatment of ICI-associated myositis in patients with thymoma [50]. The gene discussed is IL6; the disease is myositis disease.